Cedric O’Gorman, MD

  • 2Articles
  • 72.7KReads1
  • 2022–2024Active
  • 27Collaborators
  • 142Citations2

About

Cedric O’Gorman, MD, is affiliated with Relmada Therapeutics, Inc, Coral Gables, Florida. His publications focus on clinical trials evaluating the efficacy and safety of novel treatments for major depressive disorder (MDD), including esmethadone (REL-1017) and AXS-05 (dextromethorphan-bupropion). He has contributed to phase 3 randomized controlled studies addressing patients with inadequate response to standard antidepressants.

Publications

JCP
Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

June 17, 2024

Although this trial of esmethadone did not meet its primary outcome, some secondary and post hoc outcomes were promising.
, , , et al
JCP
Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD
Original Research

Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in MDD

May 30, 2022

Altered glutamatergic neurotransmission has been implicated in the pathogenesis of depression. This phase 3 trial evaluated the efficacy and safety of AXS-05 (dextromethorphan-bupropion) in the treatment of major depressive...
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe